Genocea Hit With Securities Suit After Herpes-Drug Flop
Genocea Biosciences Inc. hid its inability to finance ongoing trials for a genital herpes immunotherapy, according to a proposed class action filed Friday in Massachusetts by investors who said they were...To view the full article, register now.
Already a subscriber? Click here to view full article